SNX18P3: A Potential Drug Target and Biomarker (G100418975)
SNX18P3: A Potential Drug Target and Biomarker
SNX18P3 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. Its primary function is to regulate the growth and differentiation of neural cells, specifically those of the neuron class. SNX18P3 has been identified as a potential drug target and biomarker due to its unique structure and the involvement of several diseases, including cancer, neurodegenerative disorders, and gastrointestinal diseases.
The protein SNX18P3 is composed of 215 amino acid residues and has a calculated molecular mass of 33.1 kDa. It is a single transmembrane protein that is expressed in the brain, pancreas, and gastrointestinal tract, as well as other organs and tissues. The primary function of SNX18P3 is to regulate the growth and differentiation of neural cells, specifically those of the neuron class.
SNX18P3 plays a crucial role in the development, maintenance, and survival of neural cells. It is involved in the regulation of neuron stem cell proliferation, differentiation, and survival, as well as the regulation of neuron axon outgrowth. SNX18P3 has been shown to play a role in the development of various neurological and psychiatric disorders, including cancer, neurodegenerative disorders, and gastrointestinal diseases.
As a potential drug target, SNX18P3 is attractive due to its unique structure and the involvement of several diseases. SNX18P3 has been shown to interact with several drug targets, including the androgen receptor, the EGFR signaling pathway, and the NF-kappa-B signaling pathway. These interactions make SNX18P3 an attractive target for small molecule inhibitors, as well as antibodies that target specific regions of the protein.
In addition to its potential as a drug target, SNX18P3 is also a potential biomarker for several diseases. Its expression has been shown to be elevated in several diseases, including cancer, neurodegenerative disorders, and gastrointestinal diseases. Additionally, SNX18P3 has been shown to have potential as a diagnostic biomarker for several diseases, including neurodegenerative disorders and gastrointestinal diseases.
The identification of SNX18P3 as a potential drug target and biomarker has important implications for the development of new treatments for a variety of diseases. By targeting SNX18P3 with small molecule inhibitors or antibodies, researchers may be able to treat a range of conditions, including cancer, neurodegenerative disorders, and gastrointestinal diseases. Additionally, the development of SNX18P3 as a diagnostic biomarker could lead to earlier detection and treatment of these diseases.
In conclusion, SNX18P3 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Its unique structure and involvement in the regulation of neural cell growth and differentiation make it an attractive target for small molecule inhibitors and antibodies. Further research is needed to fully understand the role of SNX18P3 in disease and to develop effective treatments and diagnostic biomarkers.
Protein Name: Sorting Nexin 18 Pseudogene 3
The "SNX18P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNX18P3 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
SNX19 | SNX2 | SNX20 | SNX21 | SNX22 | SNX24 | SNX25 | SNX27 | SNX29 | SNX29P1 | SNX29P2 | SNX3 | SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21 | SOX21-AS1 | SOX3 | SOX30 | SOX30P1 | SOX4 | SOX5 | SOX5-AS1 | SOX6 | SOX7 | SOX8 | SOX9 | SOX9-AS1
